These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15056149)

  • 61. Massive injection of liquid silicone for hemifacial atrophy.
    Franz FP; Blocksma R; Brundage SR; Ringler SL
    Ann Plast Surg; 1988 Feb; 20(2):140-5. PubMed ID: 3355060
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Poly-L-lactic-acid filling of facial lipoatrophy in HIV+ patients under tritherapy].
    Thiéry G; Coulet O; Adam S; Guyot L
    Rev Stomatol Chir Maxillofac; 2008 Apr; 109(2):103-5. PubMed ID: 18374957
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy.
    Sturm LP; Cooter RD; Mutimer KL; Graham JC; Maddern GJ
    AIDS Patient Care STDS; 2009 Sep; 23(9):699-714. PubMed ID: 19673594
    [TBL] [Abstract][Full Text] [Related]  

  • 64. HIV-associated facial lipoatrophy.
    James J; Carruthers A; Carruthers J
    Dermatol Surg; 2002 Nov; 28(11):979-86. PubMed ID: 12460289
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical and color Doppler ultrasound evaluation of polyacrylamide injection in HIV patients with severe facial lipoatrophy secondary to antiretroviral therapy.
    Faundez E; Vega N; Vera E; Vega P; Sepulveda D; Wortsman X
    Skin Res Technol; 2017 May; 23(2):243-248. PubMed ID: 27796065
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy.
    Nadarajah JT; Collins M; Raboud J; Su D; Rao K; Loutfy MR; Walmsley S
    Clin Infect Dis; 2012 Dec; 55(11):1568-74. PubMed ID: 22942210
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The "smile-and-fill" injection technique: a dynamic approach to midface volumization.
    Wang AS; Babalola O; Jagdeo J
    J Drugs Dermatol; 2014 Mar; 13(3):288-90. PubMed ID: 24595573
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Correction of facial lipoatrophy with a biodegradable material in HIV-infected patients].
    Carbonnel E; Claudy A
    Ann Dermatol Venereol; 2005; 132(6-7 Pt 1):521-4. PubMed ID: 16142098
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term inflammatory response to liquid injectable silicone, cartilage, and silicone sheet.
    Hizal E; Buyuklu F; Ozdemir BH; Erbek SS
    Laryngoscope; 2014 Nov; 124(11):E425-30. PubMed ID: 24966072
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy.
    Gooderham M; Solish N
    Dermatol Surg; 2005 Jan; 31(1):104-8. PubMed ID: 15720106
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment of facial lipoatrophy with polymethylmethacrylate among patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): impact on the quality of life.
    Quintas RC; de França ER; de Petribú KC; Ximenes RA; Quintas LF; Cavalcanti EL; Kitamura MA; Magalhães KA; Paiva KC; Filho DB
    Int J Dermatol; 2014 Apr; 53(4):497-502. PubMed ID: 24602032
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cheek augmentation with Bio-Alcamid in facial lipoatrophy in HIV seropositive patients.
    Hönig J
    J Craniofac Surg; 2008 Jul; 19(4):1085-8. PubMed ID: 18650737
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Early and late complications of polyalkylimide gel (Bio-Alcamid)®.
    Nelson L; Stewart KJ
    J Plast Reconstr Aesthet Surg; 2011 Mar; 64(3):401-4. PubMed ID: 20637713
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Polyacrylamide gel for facial wasting rehabilitation: how many milliliters per session?
    Rauso R; Gherardini G; Parlato V; Amore R; Tartaro G
    Aesthetic Plast Surg; 2012 Feb; 36(1):174-9. PubMed ID: 21638162
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Injectable silicone for facial soft-tissue augmentation.
    Webster RC; Gaunt JM; Hamdan US; Fuleihan NS; Smith RC
    Arch Otolaryngol Head Neck Surg; 1986 Mar; 112(3):290-6. PubMed ID: 3942634
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy.
    Negredo E; Puig J; Aldea D; Medina M; Estany C; Pérez-Alvarez N; Rodríguez-Fumaz C; Muñoz-Moreno JA; Higueras C; Gonzalez-Mestre V; Clotet B
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):451-5. PubMed ID: 19320569
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients.
    Borelli C; Kunte C; Weisenseel P; Thoma-Greber E; Korting HC; Konz B
    Skin Pharmacol Physiol; 2005; 18(6):273-8. PubMed ID: 16113597
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Polyacrylamide gel injection for treatment of human immunodeficiency virus-associated facial lipoatrophy: 18 months follow-up.
    Rauso R; Freda N; Parlato V; Gherardini G; Amore R; Tartaro G
    Dermatol Surg; 2011 Nov; 37(11):1584-9. PubMed ID: 21806709
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Commentary on Ten Year Follow Up After Treatment With Highly Purified Liquid Injectable Silicone for HIV Facial Lipoatrophy.
    Mandy S
    Dermatol Surg; 2019 Jul; 45(7):949. PubMed ID: 30789525
    [No Abstract]   [Full Text] [Related]  

  • 80. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging.
    Hanke CW; Redbord KP
    J Drugs Dermatol; 2007 Feb; 6(2):123-8. PubMed ID: 17373169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.